cytek biosciences inc - CTKB
CTKB
Close Chg Chg %
4.20 0.14 3.33%
Closed Market
4.34
+0.14 (3.33%)
Volume: 888.87K
Last Updated:
Feb 19, 2026, 4:00 PM EDT
Company Overview: cytek biosciences inc - CTKB
CTKB Key Data
| Open $4.20 | Day Range 4.11 - 4.42 |
| 52 Week Range 2.37 - 6.18 | Market Cap $542.15M |
| Shares Outstanding 127.87M | Public Float 115.96M |
| Beta 1.30 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.10 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 863.31K |
CTKB Performance
| 1 Week | -0.94% | ||
| 1 Month | -22.22% | ||
| 3 Months | -28.57% | ||
| 1 Year | -17.97% | ||
| 5 Years | N/A |
CTKB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About cytek biosciences inc - CTKB
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
CTKB At a Glance
Cytek Biosciences, Inc.
47215 Lakeview Boulevard
Fremont, California 94538
| Phone | 1-877-922-9835 | Revenue | 200.45M | |
| Industry | Medical Specialties | Net Income | -6,020,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 3.854% | |
| Fiscal Year-end | 12 / 2025 | Employees | 648 | |
| View SEC Filings |
CTKB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.229 |
| Price to Book Ratio | 2.119 |
| Price to Cash Flow Ratio | 33.40 |
| Enterprise Value to EBITDA | -47.299 |
| Enterprise Value to Sales | 2.981 |
| Total Debt to Enterprise Value | 0.046 |
CTKB Efficiency
| Revenue/Employee | 309,341.049 |
| Income Per Employee | -9,290.123 |
| Receivables Turnover | 3.308 |
| Total Asset Turnover | 0.401 |
CTKB Liquidity
| Current Ratio | 5.859 |
| Quick Ratio | 5.21 |
| Cash Ratio | 4.107 |
CTKB Profitability
| Gross Margin | 55.427 |
| Operating Margin | -11.535 |
| Pretax Margin | -2.844 |
| Net Margin | -3.003 |
| Return on Assets | -1.204 |
| Return on Equity | -1.526 |
| Return on Total Capital | -1.422 |
| Return on Invested Capital | -1.444 |
CTKB Capital Structure
| Total Debt to Total Equity | 7.014 |
| Total Debt to Total Capital | 6.554 |
| Total Debt to Total Assets | 5.528 |
| Long-Term Debt to Equity | 4.457 |
| Long-Term Debt to Total Capital | 4.165 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cytek Biosciences Inc - CTKB
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 127.95M | 164.04M | 193.01M | 200.45M | |
Sales Growth
| +37.82% | +28.20% | +17.67% | +3.85% | |
Cost of Goods Sold (COGS) incl D&A
| 48.81M | 62.46M | 83.59M | 89.35M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.24M | 5.70M | 9.23M | 10.49M | |
Depreciation
| 908.00K | 4.87M | 5.93M | 6.79M | |
Amortization of Intangibles
| 334.00K | 835.00K | 3.30M | 3.70M | |
COGS Growth
| +18.67% | +27.98% | +33.82% | +6.89% | |
Gross Income
| 79.14M | 101.57M | 109.43M | 111.11M | |
Gross Income Growth
| +53.05% | +28.34% | +7.73% | +1.54% | |
Gross Profit Margin
| +61.86% | +61.92% | +56.69% | +55.43% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 69.76M | 102.78M | 135.77M | 134.23M | |
Research & Development
| 24.44M | 34.86M | 44.15M | 39.40M | |
Other SG&A
| 45.31M | 67.92M | 91.62M | 94.83M | |
SGA Growth
| +83.33% | +47.34% | +32.10% | -1.14% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 230.00K | 600.00K | 1.50M | (9.90M) | |
EBIT after Unusual Expense
| 9.16M | (1.80M) | (27.84M) | (13.22M) | |
Non Operating Income/Expense
| (1.48M) | 5.64M | 14.21M | 7.52M | |
Non-Operating Interest Income
| 49.00K | 4.62M | 6.41M | 3.06M | |
Equity in Earnings of Affiliates
| - | - | 40.00K | 40.00K | - |
Interest Expense
| - | 1.74M | 2.57M | 2.07M | |
Interest Expense Growth
| - | +422.82% | +47.79% | -19.51% | |
Gross Interest Expense
| - | 1.74M | 2.57M | 2.07M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 5.94M | 1.26M | (15.71M) | (5.70M) | |
Pretax Income Growth
| -58.85% | -78.78% | -1,346.75% | +63.72% | |
Pretax Margin
| +4.64% | +0.77% | -8.14% | -2.84% | |
Income Tax
| 2.91M | (1.22M) | (3.56M) | 320.00K | |
Income Tax - Current - Domestic
| 4.11M | 8.62M | 4.94M | 2.38M | |
Income Tax - Current - Foreign
| 601.00K | 1.44M | 1.53M | 830.00K | |
Income Tax - Deferred - Domestic
| (3.11M) | (11.07M) | (9.95M) | (3.20M) | |
Income Tax - Deferred - Foreign
| 1.31M | (211.00K) | (82.00K) | 316.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | 40.00K | 40.00K | - |
Other After Tax Income (Expense)
| - | - | - | (3.00M) | - |
Consolidated Net Income
| 26.00K | 2.48M | (12.15M) | (6.02M) | |
Minority Interest Expense
| - | - | 26.00K | (92.00K) | - |
Net Income
| - | 2.58M | (12.15M) | (6.02M) | |
Net Income Growth
| - | -100.00% | -571.58% | +50.44% | |
Net Margin Growth
| - | +1.57% | -6.29% | -3.00% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | 2.58M | (12.15M) | (6.02M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | 2.58M | (12.15M) | (6.02M) | |
EPS (Basic)
| - | 0.0192 | -0.0898 | -0.0461 | |
EPS (Basic) Growth
| - | -100.00% | -567.71% | +48.66% | |
Basic Shares Outstanding
| 133.75M | 134.51M | 135.28M | 130.61M | |
EPS (Diluted)
| - | 0.0186 | -0.0898 | -0.0461 | |
EPS (Diluted) Growth
| - | -100.00% | -582.80% | +48.66% | |
Diluted Shares Outstanding
| 133.75M | 138.56M | 135.28M | 130.61M | |
EBITDA
| 10.63M | 4.50M | (17.11M) | (12.63M) | |
EBITDA Growth
| -25.47% | -57.68% | -480.50% | +26.19% | |
EBITDA Margin
| +8.31% | +2.74% | -8.87% | -6.30% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 6.00 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.075 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.142 | |
| Last Quarter’s Earnings | -0.03 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.128 | Next Fiscal Year Estimate | -0.075 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 5 | 4 |
| Mean Estimate | -0.08 | -0.04 | -0.14 | -0.08 |
| High Estimates | -0.04 | -0.01 | -0.01 | 0.10 |
| Low Estimate | -0.12 | -0.07 | -0.27 | -0.22 |
| Coefficient of Variance | -54.97 | -73.60 | -84.71 | -218.95 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Cytek Biosciences Inc - CTKB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cytek Biosciences Inc - CTKB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 7, 2025 | William D. McCombe Chief Financial Officer | 330,882 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | William D. McCombe Chief Financial Officer | 208,816 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Valerie T. Barnett CHIEF LEGAL OFFICER | 275,735 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Valerie T. Barnett CHIEF LEGAL OFFICER | 174,013 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Wen Bin Jiang PRESIDENT AND CEO; Director | 735,294 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Wen Bin Jiang PRESIDENT AND CEO; Director | 464,037 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Ming Yan CHIEF TECHNOLOGY OFFICER; Director | 156,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Ming Yan CHIEF TECHNOLOGY OFFICER; Director | 98,607 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Philippe Busque SVP, GLOBAL SALES AND SERVICES | 91,911 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Philippe Busque SVP, GLOBAL SALES AND SERVICES | 58,004 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Valerie T. Barnett CHIEF LEGAL OFFICER | 7,394 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 21, 2025 | Wen Bin Jiang PRESIDENT AND CEO; Director | 24,788 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 21, 2025 | Ming Yan CHIEF TECHNOLOGY OFFICER; Director | 7,275 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |